| Species |
Mouse |
| Protein Construction |
IFN alpha 1 (Cys24-Lys189)_x000D_
Accession # P01572 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human IFN alpha/beta R1, His Tag captured on CM5 Chip via antihis antibody can bind IFN alpha 1 hFc Chimera, Mouse in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
45.88 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IFN-α, a cytokine expressed in human islets from individuals affected by type 1 diabetes, plays a key role in the pathogenesis of diabetes by upregulating inflammation, endoplasmic reticulum (ER) stress and MHC class I overexpression, three hallmarks of islet histology in early type 1 diabetes. |
| Synonyms |
Interferon alpha-1/13;IFN-alpha-1/13;Interferon alpha-D;LeIF D; IFNalpha 1; IFN alpha1;IFNA1;IFN-alpha-1;Interferon alpha 1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
